Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
Eva Choong, Chakradhara Rao Satyanarayana Uppugunduri, Denis Marino...
https://pubmed.ncbi.nlm.nih.gov/29189665/Actively Recruiting
Led by St. Anna Kinderkrebsforschung · Updated on 2026-09-04
1800
Participants Needed
119
Research Sites
N/A
Total Duration
Researchers are conducting a multinational phase III study to optimize therapy for children and adolescents with acute lymphoblastic leukemia ALL in complete remission who require allogeneic hematopoietic stem cell transplantation HSCT with a myeloablative conditioning regimen. The study aims to compare chemotherapy-based conditioning regimens with total body irradiation TBI combined with etoposide, focusing on treatment outcomes and side effects. This research addresses the need for safer conditioning options due to the significant long-term toxicities associated with TBI in growing patients. Participants receive different conditioning regimens before HSCT based on age, donor type, and country-specific protocols. The main options include TBI with etoposide for patients older than 4 years, and chemotherapy combinations such as fludarabine, thiotepa, treosulfan, busulfan, and cyclophosphamide for younger patients or those ineligible for TBI. Various donor types, including matched sibling donors, matched unrelated donors, and mismatched donors, are included, with additional treatments like ATG or T-cell depletion depending on donor matching. Throughout the study, participants undergo regular evaluations including survival monitoring and adverse event tracking for up to 10 years. Assessments focus on overall survival, event-free survival, relapse, and treatment-related toxicity. Data collection includes long-term follow-up to investigate factors affecting outcomes such as immune recovery, graft-versus-host disease, and pharmacogenomics. The total study duration can extend to several years to thoroughly assess late effects and survival rates.
CONDITIONS
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
C
Christina Peters, Prof. MD PhD
T
Tijana Frank, MD, MScEng
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
St. Anna Kinderkrebsforschung
Lead Sponsor
ALL SCTped Forum
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Several days before transplantation
Participants receive a conditioning regimen before stem cell transplantation. This may include total body irradiation with etoposide or chemotherapy combinations such as fludarabine, thiotepa, treosulfan, busulfan, and cyclophosphamide based on age and donor type.
Daily visits during conditioning
Duration - 1 day
Participants undergo allogeneic hematopoietic stem cell transplantation following conditioning to replace diseased bone marrow cells.
Single visit for transplantation procedure
Duration - Up to 10 years
Participants are monitored regularly for survival, relapse, adverse events, and long-term effects over the course of up to 10 years.
Regular follow-up visits at scheduled intervals
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Eva Choong, Chakradhara Rao Satyanarayana Uppugunduri, Denis Marino...
https://pubmed.ncbi.nlm.nih.gov/29189665/Christina Peters, Jean-Hugues Dalle, Franco Locatelli...
https://pubmed.ncbi.nlm.nih.gov/33332189/Peter Bader, Ulrike Pötschger, Jean-Hugues Dalle...
https://pubmed.ncbi.nlm.nih.gov/37738088/Krzysztof Kalwak, Laura M Moser, Ulrike Pötschger...
https://pubmed.ncbi.nlm.nih.gov/39602342/R Greco, A Ruggeri, D P McLornan...
https://pubmed.ncbi.nlm.nih.gov/40926035/Jochen Buechner, Ulrike Poetschger, Peter Bader...
https://pubmed.ncbi.nlm.nih.gov/41259231/Sergio M Gómez, Marcela A Varela, Claudia Ruiz...
https://pubmed.ncbi.nlm.nih.gov/33974585/Adriana Balduzzi, Evgenia Glogova, Christina Peters...
https://pubmed.ncbi.nlm.nih.gov/40820816/Khalil Ben Hassine, Yvonne Gloor, Isabelle Dupanloup...
https://pubmed.ncbi.nlm.nih.gov/41779961/Sarah K Tasian, Christina Peters
https://pubmed.ncbi.nlm.nih.gov/33242441/St. Anna Kinderkrebsforschung
Lead Sponsor
ALL SCTped Forum
Collaborating Sponsor